Q3 2021 Financial Presentation2021-11-04 The Executive Managment in Ascelia Pharma presents a business update and the quarterly results InvestorGenväg till IR & Media IR & Media Key downloads Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionalsAscelia Pharma publishes Annual Report for 2021Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agentQuarterly Report Q3 2021: Oncoral – entering clinical collaborationQuarterly Report Q2 2021: Preparing Oncoral for the next level